Drugs Made In America Acquisition II Corp - Units (1 Ord Shs & 1 Rts) DMIIU Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$10.26 up $0.03, 0.29% at close Nov 6
Last close · Previous close $10.23
- Market cap
- $653.56MAt the Nov 6 close
- Dividend yield
- NoneLast 12 months
Price chart
$10.26up $0.06, 0.59%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$10.23Nov 5
- Volume392.00Nov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume459.00Last 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $9.97 to $10.80; now $10.26
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
DMIIU beat the S&P 500 in 2 of 4 periods.
| Period | DMIIU and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | DMIIU: up 0.6% S&P 500: down 5.6% | DMIIU beat the S&P 500 by 6.2 percentage points Beat |
| 3M | DMIIU: up 1.0% S&P 500: down 4.1% | DMIIU beat the S&P 500 by 5.1 percentage points Beat |
| YTD | DMIIU: up 2.4% S&P 500: up 8.7% | DMIIU trailed the S&P 500 by 6.3 percentage points Trailed |
| 1Y | DMIIU: up 2.2% S&P 500: up 10.9% | DMIIU trailed the S&P 500 by 8.7 percentage points Trailed |
$10,000 invested in DMIIU a year ago (Nov 6, 2025) would be worth about $10,224 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $11,088.
DMIIU beat the S&P 500 in 2 of 4 periods.
| Period | DMIIU and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | DMIIU: up 0.6% S&P 500: down 5.6% | DMIIU beat the S&P 500 by 6.2 percentage points Beat |
| 3M | DMIIU: up 1.0% S&P 500: down 4.3% | DMIIU beat the S&P 500 by 5.3 percentage points Beat |
| YTD | DMIIU: up 2.4% S&P 500: up 7.8% | DMIIU trailed the S&P 500 by 5.4 percentage points Trailed |
| 1Y | DMIIU: up 2.2% S&P 500: up 9.7% | DMIIU trailed the S&P 500 by 7.5 percentage points Trailed |
$10,000 invested in DMIIU a year ago (Nov 6, 2025) would be worth about $10,224 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $10,969.
All-time high
$10.26
Closing high on .
Split-adjusted daily closes since Sep 25, 2025.
Stock splits
DMIIU hasn’t split since its price history begins in 2025.
Valuation
The Nov 6 close compared with reported results. 12-month figures aren’t available until four quarters are reported. Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
Not available
12-month figures aren’t available until four quarters are reported.
Other valuation measures
- $653.25MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Sep 30, 2025 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own DMIIU DCF in Excel. Value Drugs Made In America Acquisition II Corp - Units (1 Ord Shs & 1 Rts) with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY25, the quarter ended Sep 30, 2025, and balance-sheet figures are as of Sep 30, 2025. 12-month figures aren’t available until four quarters are reported.
Revenue and net income
12-month figures aren’t available until four quarters are reported.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | Not reported | Not reported | Not reported |
| Q2 FY25 (Jun 30, 2025) | Not reported | Not reported | Not reported |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$46.16K | $0.00 |
| Period | Revenue | Net income | Diluted EPS |
|---|
Margins
- Gross
- Operating
- Net
The lines show each quarter. What margins tell you
Cash flow
12-month figures aren’t available until four quarters are reported.
Shareholder returns
12-month figures aren’t available until four quarters are reported.
Balance sheet
- $500.42MAs of Sep 30, 2025
Cash plus short- and long-term marketable securities on the Sep 30, 2025 balance sheet.
- Total debt$0.00As of Sep 30, 2025
- Net cash$500.42MAs of Sep 30, 2025
- 1.32As of Sep 30, 2025
Current assets divided by current liabilities on the Sep 30, 2025 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
12-month figures aren’t available until four quarters are reported.
About Drugs Made In America Acquisition II Corp - Units (1 Ord Shs & 1 Rts)
Drugs Made In America Acquisition II Corp - Units (1 Ord Shs & 1 Rts)
- Sector
- Industrials
- Industry
- Shell Companies
- Headquarters
- Florida, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
DMIIU news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
DMIIU stock FAQ
What is DMIIU stock’s price today?
Drugs Made In America Acquisition II Corp - Units (1 Ord Shs & 1 Rts) (DMIIU) traded at $10.26 at the close on , up $0.03 (0.29%) from the previous close of $10.23. Over the past 52 weeks it has traded between $9.97 and $10.80.
What is Drugs Made In America Acquisition II Corp - Units (1 Ord Shs & 1 Rts)’s market cap?
Drugs Made In America Acquisition II Corp - Units (1 Ord Shs & 1 Rts)’s market capitalization is about $653.6 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $10.26 (how market cap works). Drugs Made In America Acquisition II Corp - Units (1 Ord Shs & 1 Rts) reported 63.70M shares outstanding at the end of its latest quarter ().
Does DMIIU pay a dividend?
Drugs Made In America Acquisition II Corp - Units (1 Ord Shs & 1 Rts) hasn’t paid a dividend in the last twelve months.
What is DMIIU’s 52-week high and low?
Over the past 52 weeks DMIIU has traded as low as $9.97 and as high as $10.80. At $10.26 at the close on , it is 5.0% below that high and 2.9% above the low.
What is DMIIU’s all-time high?
DMIIU’s highest closing price was $10.26 on , adjusted for stock splits.
Has DMIIU stock ever split?
No. DMIIU hasn’t split since its price history begins in 2025.
How has DMIIU stock performed?
Including dividends and measured to the close on , DMIIU has returned +2.4% so far this year and +2.2% over the past year. Over the same periods the S&P 500, measured by SPY, returned +8.7% and +10.9%. Past performance doesn’t predict future returns.
What sector and industry is Drugs Made In America Acquisition II Corp - Units (1 Ord Shs & 1 Rts) in?
Drugs Made In America Acquisition II Corp - Units (1 Ord Shs & 1 Rts) is in the Industrials sector and the Shell Companies industry, and is headquartered in Florida, USA.
What exchange does DMIIU trade on?
Drugs Made In America Acquisition II Corp - Units (1 Ord Shs & 1 Rts) trades on the Nasdaq under the ticker symbol DMIIU. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.